Subcutaneous Rheumatoid Nodules Treatment
Links shared publicly online about this topic
SIMPONI" (Golimumab) Receives Positive Opinion from Chmp for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
jnj.com — “Johnson & Johnson news and information regarding our operations, products, leaders, and our charitable giving.” View full resource at jnj.com
Most Recently Shared on June 26, 2009 at 4:22 pm By:
eyeonfda Health Lawyer and Pharma
J&Js SIMPONIâ„¢ (Gets Thumbs Up from Chmp for 1xMonth Subcut Trtmnt of RA, Psoriatic Arthritis and Ankylosing Spondylitis http://bit.ly/5oiTM
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
drugs.com — “Orencia (abatacept) is used for the treatment of rheumatoid arthritis. Information from Drugs.com includes Orencia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 2, 2011 at 12:27 am By:
FDA Approves Subcutaneous Formulation of Orencia - http://bit.ly/pjN8oc
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
drugs.com — “Orencia (abatacept) is used for the treatment of rheumatoid arthritis. Information from Drugs.com includes Orencia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 2, 2011 at 12:14 am By:
Drugs and Devices OW OW Health
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-A... http://bit.ly/qnjY9u #drug
U.S. Food And Drug Administration Accepts Supplemental Biologics License Application For Subcutaneous Formulation Of ORENCIA® (abatacept)
medicalnewstoday.com — “Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2010 at 6:55 pm By:
MNT Arthritis News Health News
U.S. Food And Drug Administration Accepts Supplemental Biologics License Application For Subcutaneous Formulation Of O... http://mnt.to/3NPD
New MRI Data Confirm Simponi (Golimumab) Efficacy in Treatment of Rheumatoid Arthritis - Drugs.com MedNews
drugs.com — “MONTREAL, Nov. 30 CNW - Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of g” View full resource at drugs.com
Most Recently Shared on November 30, 2010 at 7:14 pm By:
Drugs and Devices OW OW Health
New MRI Data Confirm Simponi (Golimumab) Efficacy in Treatment of Rheumatoid Arthritis: MONTREAL, Nov. 30 ... http://bit.ly/ek7xoa #drug
Rheumatoid Arthritis Causes, Symptoms, Signs, Diagnosis and Treatment by MedicineNet.com
medicinenet.com — “Learn more about rheumatoid arthritis, an autoimmune disease that causes chronic joint inflammation, which has symptoms that include stiffness, fever, muscle and joint aches, loss of appetite, and fatigue. Treatment of rheumatoid arthritis incorporates the use of first-line drugs (aspirin and corticosteroids for pain and inflammation) and second-line drugs (methotrexate and hydroxychloroquine to prevent joint destruction and promote remission).” View full resource at medicinenet.com
Most Recently Shared on July 13, 2010 at 11:37 pm By:
Susan Scroggins Health Advocate and Active Health Library
Great site for rheumatoid arthritis information: http://bit.ly/KV3gp
New Magnetic Resonance Imaging (MRI) Data Show Efficacy Of SIMPONI® In Treatment Of Rheumatoid Arthritis
medicalnewstoday.com — “Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI® (golimumab) 50 mg plus methotrexate resulted in” View full resource at medicalnewstoday.com
Most Recently Shared on November 9, 2010 at 4:05 pm By:
MNT MRI / Ultrasound Health News
New Magnetic Resonance Imaging (MRI) Data Show Efficacy Of SIMPONI® In Treatment Of Rheumatoid Arthritis http://mnt.to/3Mgk
Rheumatology Medical News about Methotrexate Arthritis, Rheumatoid
mdlinx.com — “Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study” View full resource at mdlinx.com
Most Recently Shared on June 15, 2010 at 2:30 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful... http://bit.ly/cET3nK #Rheumatology
Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta
news-medical.net — “Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.” View full resource at news-medical.net
Most Recently Shared on August 17, 2010 at 5:07 pm By:
Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta: Merck is pleased to ann... http://bit.ly/bD5YP5
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
eyeonfda
Author of the blog Eye on FDA - www.eyeonfda.com
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
